Items where authors include "Evans, TRJ"

Article

Twelves, C, Anthoney, A, Savulsky, CI et al. (9 more authors) (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120 (6). pp. 579-586. ISSN 0007-0920

Lindsay, CR, Shaw, EC, Blackhall, F et al. (26 more authors) (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. Esmo Open, 3 (6). e000408. ISSN 2059-7029

Meyer, T, Fox, R, Ma, YT et al. (15 more authors) (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology, 2 (8). pp. 565-575. ISSN 2468-1253

Propper, D, Jones, K, Anthoney, DA et al. (8 more authors) (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16 (1). 779. ISSN 1471-2407

Cameron, DA, Anderson, A, Toy, E et al. (9 more authors) (2002) Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? British Journal of Cancer, 87 (12). pp. 1365-1369. ISSN 0007-0920

Conference or Workshop Item

Stavraka, C, Evans, TRJ, Dunlop, J et al. (6 more authors) (2020) Abstract P2-16-15: 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study. In: Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas, 10-14 Dec 2019, San Antonio, Texas, USA.